TY - JOUR T1 - <span hwp:id="article-title-1" class="article-title">Intensive glucose control did not prevent important complications in type 2 diabetes</span><span hwp:id="article-title-2" class="sub-article-title">Commentary</span> JF - Evidence Based Nursing JO - Evid Based Nurs SP - 12 LP - 13 DO - 10.1136/ebn.12.1.12 VL - 12 IS - 1 AU - Diana Sherifali Y1 - 2009/01/01 UR - http://ebn.bmj.com/content/12/1/12.abstract N2 - A PatelDr A Patel, University of Sydney, Sydney, New South Wales, Australia; apatel@george.org.auIn type 2 diabetes, does intensive glucose control prevent adverse outcomes more than standard glucose control?Design:randomised controlled trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]).Allocation:concealed.Blinding:blinded (outcome adjudication committee).Follow-up period:median 5 years.Setting:215 centres in 20 countries worldwide.Patients:11 140 patients ⩾55 years of age (mean age 66 y, 58% men) who had type 2 diabetes and a history of, or risk factors for, vascular disease. Patients requiring insulin were excluded.Intervention:intensive glucose control with gliclazide, modified-release, 30–120 mg/day, and other non-sulfonylurea drugs as needed to achieve a target glycated haemoglobin (HbA1c) concentration ⩽6.5% (n = 5571) or standard glucose control with drugs other than gliclazide (n = 5569).Outcomes:composite of major macrovascular events (non-fatal myocardial infarction or stroke, or death from cardiovascular causes) and composite of major microvascular events (new or worsening nephropathy or retinopathy). Secondary outcomes included new-onset microalbuminuria and severe hypoglycaemia.Patient follow-up:95% (intention-to-treat analysis).The … ER -